# NSI-189 for depression: who benefited in a phase 2 trial

Source: https://pepvault.app/research/nsi-189-johe-2020

Last updated: 2026-11-17

Use: © PepVault. Read and cite with a link. Copying, bulk scraping, rewriting or republishing is not permitted (https://pepvault.app/terms#content).

[Research](https://pepvault.app/research) [NSI-189](https://pepvault.app/research#nsi-189)

Randomized trial · people

# NSI-189 80 mg beat placebo in moderate, not severe, depression

Checked against the paper November 2026 Randomized trial [Published by PepVault](https://pepvault.app/guides/how-we-research)

## The takeaway

In this trial, the antidepressant benefit of NSI-189 showed up in moderate rather than severe depression. Because it came from an after-the-fact split, it is a lead to test, not a settled result.

- **Kind:** Randomized trial
- **Studied in:** People
- **Number studied:** 220
- **Published:** 2020
- **Journal:** Ann Clin Psychiatry

## What they tested

Did the effect of NSI-189 on depression and thinking skills differ depending on how severe a person's depression was at the start?

## How the study was done

A randomized, placebo-controlled phase 2 trial in 220 patients with major depressive disorder, who took NSI-189 40 mg, NSI-189 80 mg or placebo (a dummy pill) daily for 12 weeks, tested in two 6-week stages. This analysis was done after the trial ended (post hoc) and split patients by a starting score of 30 on the MADRS, a depression rating scale.

<!--promo-->

PepVault for iPhone

## Taking NSI-189? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-flow&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## What they found

Splitting patients by how severe their depression was at the start made the effect of NSI-189 look larger. In patients with moderate depression (MADRS below 30), the 80 mg arm did significantly better than placebo on the MADRS-6 score. In patients with severe depression (MADRS of 30 or more), the difference was not significant. On CogScreen measures of thinking skills, 11/36 (31%) improved significantly in the moderate group, compared with 5/36 (14%) in the severe group and 7/36 (19%) across the whole study.

## What it doesn’t show

This was a post hoc subgroup analysis, so the moderate-versus-severe split was not the trial's original test and needs checking in a new trial. The significant depression result came from one dose on one version of the scale, over 12 weeks.

## The paper

Johe et al. NSI-189 phosphate, a novel neurogenic compound, selectively benefits moderately depressed patients: A post-hoc analysis of a phase 2 study of major depressive disorder. Ann Clin Psychiatry. 2020.

- [PubMed (PMID 32722729)](https://pubmed.ncbi.nlm.nih.gov/32722729/)

## The compound

- [NSI-189: how it works, half-life, studied range and evidence](https://pepvault.app/peptides/nsi-189)
- [NSI-189 dose guide](https://pepvault.app/lab/dosage/nsi-189)

## With this study

### NSI-189

- [NSI-189: the full reference](https://pepvault.app/peptides/nsi-189)
- [NSI-189 dose guide](https://pepvault.app/lab/dosage/nsi-189)

### Studies

- [NSI-189 eased nerve damage and memory problems in diabetic rats](https://pepvault.app/research/nsi-189-jolivalt-2022)
- [NSI-189 protected nerves and memory in diabetic mice](https://pepvault.app/research/nsi-189-jolivalt-2019)
- [All 4 studies](https://pepvault.app/research#nsi-189)

### Compared with

- [Semax vs NSI-189](https://pepvault.app/peptides/compare/semax-vs-nsi-189)

### Tools

- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)

## More studies on NSI-189

- [NSI-189 eased nerve damage and memory problems in diabetic rats](https://pepvault.app/research/nsi-189-jolivalt-2022) Animal study · rats · 2022
- [NSI-189 protected nerves and memory in diabetic mice](https://pepvault.app/research/nsi-189-jolivalt-2019) Animal study · mice · 2019
- [NSI-189 eased motor and neurological deficits after stroke in rats](https://pepvault.app/research/nsi-189-tajiri-2017) Animal study · rats · 2017
- [Every study on NSI-189](https://pepvault.app/research#nsi-189)

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed November 2026. Spot an error? [feedback@pepvault.app](mailto:feedback@pepvault.app). [How we research](https://pepvault.app/guides/how-we-research). This page reports one study; it is not medical advice.

<!--promo-->

[Track it in the app](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-next&mt=8)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking NSI-189? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-end&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

<!--promo-->

PepVault for iPhone

## Taking NSI-189? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-rail&mt=8)

7 days free on the yearly plan for new subscribers.

<!--/promo-->

## With this study

### NSI-189

- [NSI-189: the full reference](https://pepvault.app/peptides/nsi-189)
- [NSI-189 dose guide](https://pepvault.app/lab/dosage/nsi-189)

### Studies

- [NSI-189 eased nerve damage and memory problems in diabetic rats](https://pepvault.app/research/nsi-189-jolivalt-2022)
- [NSI-189 protected nerves and memory in diabetic mice](https://pepvault.app/research/nsi-189-jolivalt-2019)
- [All 4 studies](https://pepvault.app/research#nsi-189)

### Compared with

- [Semax vs NSI-189](https://pepvault.app/peptides/compare/semax-vs-nsi-189)

### Tools

- [Half-life calculator](https://pepvault.app/tools/peptide-half-life-calculator)

### Terms on this page

- [Placebo](https://pepvault.app/glossary/placebo)

<!--promo-->

PepVault for iPhone

## Taking NSI-189? Keep your own record

Log each dose, your weight and how you feel, in one place.

[Download on the App Store](https://apps.apple.com/app/apple-store/id6779318649?pt=129020030&ct=study-card-sticky&mt=8)

7 days free on the yearly plan for new subscribers.

[Explore the live demo](https://pepvault.app/login)

<!--/promo-->

## Research

- [All studies](https://pepvault.app/research)
- [Every study on NSI-189](https://pepvault.app/research#nsi-189)

## The library

- [NSI-189](https://pepvault.app/peptides/nsi-189)
- [NSI-189 dose guide](https://pepvault.app/lab/dosage/nsi-189)
- [The peptide reference library](https://pepvault.app/peptides)

## How we work

- [How we research](https://pepvault.app/guides/how-we-research)
- [How we check the library](https://pepvault.app/about#library)

PepVault is a research and tracking resource, not medical advice. Ranges are what studies used, never a dose for you. Brand names are trademarks of their owners; PepVault is independent of them.

PepVault is a private research and tracking tool, not medical advice. The information here is reference material from published literature and community use — always verify it and discuss any protocol with a qualified clinician before changing it.

© 2026 PepVault. Our text, data and tools may not be copied, scraped or republished without [permission](https://pepvault.app/terms#content).
